Search - tctmd.com

Displaying 841 - 860 of 1266

Sort: Relevancy | Date

News Conference News AHA 2018

Concerning Decline in Antibiotic Prophylaxis for Infective Endocarditis

Todd Neale

November 19, 2018

News Daily News

FDA Allows Claim About Oleic Acid’s Possible Heart Benefits on Labeling

Todd Neale

November 19, 2018

News Conference News AHA 2018

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Daily News

‘Accelerated Atherosclerosis’ Not Uncommon in Arteries of Young People

Caitlin E. Cox

November 15, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Daily News

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

Michael O'Riordan

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

L.A. McKeown

October 30, 2018

News Daily News

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Michael O'Riordan

October 30, 2018

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

Advertisement

Concerning Decline in Antibiotic Prophylaxis for Infective Endocarditis

FDA Allows Claim About Oleic Acid’s Possible Heart Benefits on Labeling

Greater Need for Cooperative Care in Women’s Heart Health, Two Studies Suggest

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

‘Accelerated Atherosclerosis’ Not Uncommon in Arteries of Young People

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

Higher Fitness Again Tied to a Lower Risk of Death, Including CVD Mortality

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content